M&T Bank Corp Has $6.54 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

M&T Bank Corp lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,090 shares of the medical research company's stock after selling 13,872 shares during the quarter. M&T Bank Corp's holdings in IQVIA were worth $6,539,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new position in IQVIA during the first quarter worth $26,000. Golden State Wealth Management LLC lifted its holdings in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $39,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of IQVIA in the 4th quarter worth approximately $44,000. Institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Robert W. Baird cut their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Evercore ISI boosted their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $222.45.

IQVIA Stock Down 1.7%

IQVIA stock traded down $2.80 during midday trading on Friday, reaching $162.73. The stock had a trading volume of 1,156,699 shares, compared to its average volume of 1,660,352. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. The firm's fifty day simple moving average is $151.96 and its 200-day simple moving average is $171.98. The stock has a market capitalization of $28.15 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.